RMC-6236 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is RMC-6236 safe for humans?
What makes the drug RMC-6236 unique for cancer treatment?
Who Is on the Research Team?
Revolution Medicines, Inc.
Principal Investigator
Revolution Medicines, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have specific RAS mutations, who've already tried standard treatments. They need to be relatively healthy and active (ECOG status of 0 or 1), with good organ function. It's not for those with primary brain tumors, untreated brain metastases, issues absorbing oral meds, or other serious health problems.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive escalating doses of RMC-6236 to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RMC-6236
Find a Clinic Near You
Who Is Running the Clinical Trial?
Revolution Medicines, Inc.
Lead Sponsor